|Data used to calculate the probability of CP|
|Mild (GMFCS level I/II)||21||21||a|
|Moderate (GMFCS level III)||12||15||a|
|Severe (GMFCS level IV/V)||3||6||a|
|Mild (GMFCS level I/II)||28||49||b|
|Moderate (GMFCS level III)||8||9||b|
|Severe (GMFCS level IV/V)||5||16||b|
Total number of patients assessed and number with each outcome in each of the four trials. Note that only data on patients to whom magnesium sulphate was administered for the specific purpose of fetal neuroprotection was included in the present analyses.
aAssumed with reference to the study protocol and detailed descriptions of characteristics for each GMFCS level for children under the age of four.
bD. Rouse, MD, written communication, March 2011.
Bickford et al.
Bickford et al. BMC Health Services Research 2013 13:527 doi:10.1186/1472-6963-13-527